CGH
MEDP icon

Crossmark Global Holdings’s Medpace MEDP Stock Holding History

Crossmark Global Holdings’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Sell
6,094
-7,188
-54% -$3.32M 0.04% 340
2026
Q1 		$6.38M Buy
13,282
+2,807
+27% +$1.44M 0.09% 221
2025
Q4 		$5.88M Buy
10,475
+8,195
+359% +$4.65M 0.08% 232
2025
Q3 		$1.17M Sell
2,280
-117
-5% -$51.1K 0.02% 583
2025
Q2 		$752K Buy
2,397
+127
+6% +$38.1K 0.01% 716
2025
Q1 		$692K Buy
2,270
+315
+16% +$106K 0.01% 731
2024
Q4 		$649K Sell
1,955
-5,873
-75% -$1.99M 0.01% 728
2024
Q3 		$2.61M Buy
7,828
+1,793
+30% +$681K 0.05% 350
2024
Q2 		$2.48M Sell
6,035
-143
-2% -$56.6K 0.05% 355
2024
Q1 		$2.5M Sell
6,178
-245
-4% -$86.1K 0.05% 370
2023
Q4 		$1.97M Sell
6,423
-123
-2% -$33.2K 0.04% 402
2023
Q3 		$1.61M Buy
6,546
+2,634
+67% +$674K 0.04% 443
2023
Q2 		$997K Buy
3,912
+17
+0.4% +$3.53K 0.02% 589
2023
Q1 		$733K Buy
3,895
+92
+2% +$19K 0.02% 671
2022
Q4 		$807K Sell
3,803
-1,362
-26% -$272K 0.02% 621
2022
Q3 		$812K Sell
5,165
-316
-6% -$50.4K 0.02% 605
2022
Q2 		$820K Sell
5,481
-369
-6% -$53.4K 0.02% 631
2022
Q1 		$957K Buy
5,850
+3,220
+122% +$531K 0.02% 639
2021
Q4 		$572K Sell
2,630
-3,150
-54% -$660K 0.01% 835
2021
Q3 		$1.09M Sell
5,780
-350
-6% -$63.8K 0.03% 582
2021
Q2 		$1.08M Sell
6,130
-260
-4% -$44.9K 0.03% 582
2021
Q1 		$1.05M Buy
6,390
+50
+0.8% +$7.65K 0.03% 575
2020
Q4 		$883K Buy
6,340
+590
+10% +$74.4K 0.02% 605
2020
Q3 		$643K Sell
5,750
-210
-4% -$24.3K 0.02% 677
2020
Q2 		$554K Buy
5,960
+270
+5% +$23K 0.02% 714
2020
Q1 		$418K Sell
5,690
-50
-0.9% -$4.34K 0.02% 709
2019
Q4 		$483K Sell
5,740
-2,390
-29% -$185K 0.01% 822
2019
Q3 		$683K Sell
8,130
-130
-2% -$9.82K 0.02% 657
2019
Q2 		$540K Sell
8,260
-810
-9% -$46.7K 0.02% 777
2019
Q1 		$535K Buy
+9,070
New +$542K 0.02% 779

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crossmark Global Holdings's MEDP Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Medpace (MEDP) stake by 54% in Q2 2026, selling an estimated $3.32M and leaving 6,094 shares worth $3.23M. The position accounts for 0.04% of the portfolio, ranked #340.

Crossmark Global Holdings first reported a position in MEDP in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.38M in Q1 2026. 693 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Crossmark Global Holdings held 6,094 shares of Medpace worth $3.23M as of Q2 2026.
  • Crossmark Global Holdings sold 7,188 Medpace shares in Q2 2026, an estimated $3.32M.
  • Medpace made up 0.04% of Crossmark Global Holdings's portfolio in Q2 2026, its #340 holding.
  • Crossmark Global Holdings first reported a position in Medpace in Q1 2019 and has held it in 30 quarters since.
  • Crossmark Global Holdings's Medpace position peaked at $6.38M in Q1 2026.
  • 693 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.